COMPOUNDS FOR TREATING PD-L1 DISEASES Russian patent published in 2025 - IPC C07D207/06 C07D213/64 C07D217/04 C07D295/12 C07D401/12 C07C25/02 C07C217/58 C07C229/16 C07C309/14 A61K31/03 A61K31/132 A61K31/137 A61K31/513 A61P37/02 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I), where R^1a, R^1b, R^1c and R^1d each is independently selected from H, F, Cl, C_1-3 alkyl, C_1-3 haloalkyl and C_1-3 alkoxy groups; X¹ represents C_1-3 alkylene, optionally substituted with one or two C_1-2 alkyls; R^2a and R^2b each is independently selected from H, C_1-8 alkyl, -X²-C(O)₂R^a, -X²-OR^a, where each X² represents C_1-6 alkylene; or R^2a and R^2b are combined to form 4–8-membered ring having one cycle vertex selected from N; or R^1a and R^2a are combined to form 5–7-membered ring having one or two cycle vertices selected from O and N; or R^1b and R^2b are combined to form 5–7-membered ring having one or two cycle vertices selected from O and N; where rings formed when combining R^2a and R^2b, R^1a and R^2a or R^1b and R^2b, contain 0 or 1 substituent independently selected from -X³-C(O)₂R^a and -X³-OR^a, where X³ is a bond or C_1-6 alkylene; R³ selected from F, Cl, C_1-3 alkyl, C_1-3 alkoxy groups, C_1-3 haloalkyl, C_2-3 alkenyl and CN; n is 0; each of R⁴, R⁶, R⁷ and R⁸ is independently selected from H, halogen, C_1-6 alkyl and -X⁴-OR^a, where each X⁴ is a bond; R⁵ is selected from H, halogen, C_1-6 alkyl, -Y², -X⁵-OR^a, -X⁵-NR^aR^b, -O-X⁵-Y² and -AZ, where each X⁵ is a bond or C_1-6 alkylene and each Y² selected from C_4-8 heterocyclyl containing one N heteroatom, C_7-9 spiroheterocyclyl containing one N heteroatom, and 5–6 membered heteroaryl containing one N heteroatom, each of which is optionally further substituted with 1–4 substitutes independently selected from halogen, OH and C_1-4 alkyl; where A is selected from a bond, -O, and -N(R^a)-; Z is selected from: i) monocyclic 6-member heteroaryl ring containing one N heteroatom; and ii) 6-membered non-aromatic heterocyclic ring containing one N heteroatom; and two of R⁴, R⁵ and R⁶ adjacent carbon atoms are optionally combined to form 6-membered non-aromatic heterocyclic ring having one or two ring vertices selected from O and -N (R^b) -; where said non-aromatic heterocyclic ring is optionally substituted with an oxo group and optionally 1 substituent R^c; and at least one of R⁴, R⁵, R⁶, R⁷ and R⁸ differs from H; every R^a is independently selected from H and C_1-6 alkyl; every R^b is independently selected from H; and each R^c is independently selected from H, CN, -Y⁴, -X⁶-C(O)₂R^a and -X⁶-NR^aR^b, where each X⁶ is a bond or C_1-6 alkylene and each Y⁴ selected from C_4-8 heterocyclyl containing one or two N heteroatoms. Invention also relates to a pharmaceutical composition containing a compound of formula (I), a method of treating a disease or disorder associated with PD-1, using a compound of formula (I), using the compound of formula (I) for treating a disease or disorder associated with PD-1, and compound 1.006 specified in the claim.

EFFECT: compounds having PD-1 inhibitory activity for treating PD-1 mediated diseases.

19 cl, 1 tbl, 25 ex